Alternate channel therapy for cystic fibrosis lung disease

L Delpiano - 2023 - theses.ncl.ac.uk
Cystic Fibrosis (CF) is the most common, severe, autosomal recessive disease in the
Caucasian population, and is caused by mutations in the cystic fibrosis transmembrane …

[HTML][HTML] Targeting ion channels in cystic fibrosis

MA Mall, LJV Galietta - Journal of Cystic Fibrosis, 2015 - Elsevier
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause a
characteristic defect in epithelial ion transport that plays a central role in the pathogenesis of …

The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?

KE Oliver, MS Carlon, N Pedemonte… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Cystic fibrosis (CF), a potentially fatal genetic disease, is caused by loss-of-
function mutations in the gene encoding for the CFTR chloride/bicarbonate channel …

TMEM16A: An alternative approach to restoring airway anion secretion in cystic fibrosis?

H Danahay, M Gosling - International Journal of Molecular Sciences, 2020 - mdpi.com
The concept that increasing airway hydration leads to improvements in mucus clearance
and lung function in cystic fibrosis has been clinically validated with osmotic agents such as …

[HTML][HTML] Ion channels as targets to treat cystic fibrosis lung disease

SL Martin, V Saint-Criq, TC Hwang, L Csanády - Journal of Cystic Fibrosis, 2018 - Elsevier
Lung health relies on effective mucociliary clearance and innate immune defence
mechanisms. In cystic fibrosis (CF), an imbalance in ion transport due to an absence of …

Personalised therapies for all: Targeting alternative chloride channels in Cystic Fibrosis

MC Pinto - 2022 - repositorio.ul.pt
Cystic Fibrosis (CF) is a life-shortening genetic disorder caused by mutations in the CF
Transmembrane Conductance Regulator (CFTR) gene, which encodes a cAMP-regulated …

Pharmacological modulation of ion channels for the treatment of cystic fibrosis

MC Pinto, IAL Silva, MF Figueira… - Journal of …, 2021 - Taylor & Francis
Cystic fibrosis (CF) is a life-shortening monogenic disease caused by mutations in the gene
encoding the CF transmembrane conductance regulator (CFTR) protein, an anion channel …

Pharmacological therapy for cystic fibrosis: from bench to bedside

F Becq, MA Mall, DN Sheppard, M Conese… - Journal of Cystic …, 2011 - Elsevier
With knowledge of the molecular behaviour of the cystic fibrosis transmembrane
conductance regulator (CFTR), its physiological role and dysfunction in cystic fibrosis (CF) …

Challenges facing airway epithelial cell-based therapy for cystic fibrosis

A Berical, RE Lee, SH Randell… - Frontiers in pharmacology, 2019 - frontiersin.org
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause
the life-limiting hereditary disease, cystic fibrosis (CF). Decreased or absent functional CFTR …

[引用][C] 611 A mutation-independent role of TMEM16A for airway cystic fibrosis therapy

J Lee, H Quach, A Cho, H Nie, A Wong - Journal of Cystic Fibrosis, 2022 - Elsevier